Suppr超能文献

2019冠状病毒病大流行与心肾代谢疾病患者的风险因素测量:英国的一项回顾性研究

COVID-19 pandemic and risk factor measurement in individuals with cardio-renal-metabolic diseases: A retrospective study in the United Kingdom.

作者信息

Shabnam Sharmin, Zaccardi Francesco, Yates Tom, Islam Nazrul, Razieh Cameron, Chudasama Yogini V, Banerjee Amitava, Seidu Samuel, Khunti Kamlesh, Gillies Clare L

机构信息

Leicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, United Kingdom.

National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC), Leicester Diabetes Centre, Leicester General Hospital, Leicester, United Kingdom.

出版信息

PLoS One. 2025 Apr 24;20(4):e0319438. doi: 10.1371/journal.pone.0319438. eCollection 2025.

Abstract

BACKGROUND

Comprehensive research about changes in risk factor (RF) management of people with chronic conditions during the COVID-19 pandemic is sparse. We aimed to study the impact of the pandemic on RF assessment in people with type 2 diabetes (T2DM), cardiovascular disease (CVD), and chronic kidney disease (CKD).

METHOD

Using UK Clinical Practice Research Datalink GOLD, we identified adults with T2DM, CVD and CKD who were alive and registered two years before (March 2018 - February 2019; March 2019 - February 2020) and one year during (March 2020 - February 2021) the pandemic. We estimated the proportion of people whose RFs (systolic (SBP) and diastolic (DBP) blood pressure, total cholesterol (TC), body mass index, smoking, and HbA1c) were assessed, mean values, and the proportion of controlled at each period for each cohort, overall and by age, sex, ethnicity, and deprivation. Multivariable logistic regression was used to estimate the association of patient characteristics (age, sex, ethnicity, deprivation, and comorbidity) with the outcome of having all RFs assessed during a given period.

RESULTS

Within the T2DM cohort, 66.4% and 65.2% had assessments of HbA1c in 2018 and 2019, which reduced to 43.4% in 2020. In CVD cohort, 76.9% and 72.6% had their BP measurements (54.5% and 51.3% for TC) in 2018 and 2019 respectively, which declined to 40.6% (30.7% for TC) in 2020. In CKD cohort, BP assessments declined from 77.9% and 72.3% in 2018 and 2019 respectively to 45.0% in 2020. These findings were consistent across patient demographics. In those with T2DM, SBP and DBP increased (+1.65 mmHg and +1.02 mmHg) in 2020. Elderly people were less likely to have all their RFs assessed in 2020 in all three cohorts compared to previous years.

CONCLUSIONS

Among people with major cardiometabolic conditions, there have been substantial reductions in the assessment and control of several key RFs during the pandemic. These patients will need regular monitoring in future for the prevention of complications. Our findings also highlight the need for resilient healthcare systems to ensure continuity of care and mitigate disparities in high-risk populations.

摘要

背景

关于新冠疫情期间慢性病患者风险因素(RF)管理变化的全面研究较少。我们旨在研究疫情对2型糖尿病(T2DM)、心血管疾病(CVD)和慢性肾脏病(CKD)患者的RF评估的影响。

方法

利用英国临床实践研究数据链黄金数据库(UK Clinical Practice Research Datalink GOLD),我们确定了在疫情前两年(2018年3月至2019年2月;2019年3月至2020年2月)以及疫情期间一年(2020年3月至2021年2月)存活且登记在册的T2DM、CVD和CKD成年患者。我们估计了各队列在每个时期接受RF评估(收缩压(SBP)和舒张压(DBP)、总胆固醇(TC)、体重指数、吸烟情况和糖化血红蛋白(HbA1c))的患者比例、平均值,以及各队列在每个时期总体以及按年龄、性别、种族和贫困程度划分的控制比例。采用多变量逻辑回归来估计患者特征(年龄、性别、种族、贫困程度和合并症)与在给定时期内所有RF均接受评估这一结果之间的关联。

结果

在T2DM队列中,2018年和2019年分别有66.4%和65.2%的患者接受了HbA1c评估,2020年降至43.4%。在CVD队列中,2018年和2019年分别有76.9%和72.6%的患者进行了血压测量(TC测量分别为54.5%和51.3%),2020年降至40.6%(TC为30.7%)。在CKD队列中,血压评估从2018年的77.9%和2019年的72.3%分别降至2020年的45.0%。这些结果在不同患者人口统计学特征中均一致。在T2DM患者中,2020年SBP和DBP有所升高(分别升高1.65 mmHg和1.02 mmHg)。与前几年相比,2020年所有三个队列中的老年人接受所有RF评估的可能性均较低。

结论

在患有主要心脏代谢疾病的人群中,疫情期间几种关键RF的评估和控制大幅减少。这些患者未来需要定期监测以预防并发症。我们的研究结果还凸显了具备弹性的医疗保健系统对于确保医疗连续性以及减轻高危人群差异的必要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5fe/12021215/d19a4e914df1/pone.0319438.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验